Isis Pharmaceuticals Company Profile

20:24 EST 12th December 2018 | BioPortfolio

Isis Pharmaceuticals, Inc. is a leading drug discovery and development company, focused exclusively on the therapeutic target, RNA. Founded in 1989, Isis' mission is to develop products from its RNA-based technologies, such as antisense. Very little was known about antisense when the Company was first established, but its founders envisioned an opportunity to revolutionize the pharmaceutical industry with a more efficient and targeted means of drug discovery. Since then, Isis scientists have made tremendous progress advancing the science of antisense, unveiling capabilities that have far exceeded their expectations. Antisense drugs are the first class of drugs targeted to control expression of genes through interactions with RNA. The goal of antisense drugs is to intervene at the RNA level to prevent the production of proteins involved in disease. Antisense drugs are designed to complement and bind (hybridize) to a segment of messenger RNA (mRNA) to form a duplex. mRNA contains instructions to make proteins, including those involved in disease. The formation of this duplex or two stranded molecule prevents the RNA from functioning normally and from producing a specific protein. Antisense drugs are designed to interact specifically with the intended mRNA target. This high degree of specificity may make antisense drugs more effective and less toxic than traditional drugs. Beyond antisense, Company scientists have created another technology that exploits their knowledge of RNA. Ibis Biosciences, Inc., a wholly owned subsidiary of Isis, has developed and is commercializing the Ibis T5000 Biosensor System for rapid identification and characterization of organisms.


1896 Rutherford Road
United States of America


Phone: 760.931.9200
Fax: 760.603.2700

News Articles [322 Associated News Articles listed on BioPortfolio]

Isis Innovation: How the Oxford Sciences Innovation fund is promoting investment in the Oxfordshire region

Adam Stoten, head of Technology Transfer at Isis Innovation (the technology transfer arm of the University of Oxford) discusses the recent successes of Oxford Sciences Innovation (OSI), a fund compris...

US$ 1.5B Deal, PTV News: Apr 01, 2010

GSK and Isis to develop up to 6 drugs for rare and serious diseases

Cholesterol Hope, PTV News: Mar 18, 2010

Genzyme and Isis announce positive phase III trials for inherited high LDL drug

News Headlines, PTV News: Apr 01, 2010

A look at today's forthcoming news stories: GSK and Isis in US$ 1.5B deal to develop rare disease drugs; sanofi changes direction towards biotechnology, and Glaxo gets approval for Avodart in combinat...

News Headlines, PTV News: Mar 18, 2010

A look at today's forthcoming news stories including Genzyme and Isis announcing positive trials for rare cholesterol condition; Novartis wins European approval for meningitis vaccine and the cannabis...

PTV News: Nov 18, 2009

Top stories on November 18th, 2009: Safety concerns and delays undermine positive Isis trials NICE rejects BMS and Novartis leukaemia drug NicOx raises US$ 150M to push osteoarthritis drug Action ...

Novosom: Strategies for a Novel Liposomal Delivery Company

In this exclusive interview, Fintan Walton talks to Elias Papatheodorou, CEO of novosom, about the company’s novel liposomal technology, and the potential applications of this technology. Elias expl...

Deals and M&As this week: Aridis Pharmaceuticals, Xeris Pharmaceuticals, Astellas Pharma

Aridis Pharmaceuticals has raised $26m through an initial public offering of two million shares of its common stock priced at $13...Read More... The post Deals and M&As this week: Aridis Pharmac...

Drugs and Medications [307 Associated Drugs and Medications listed on BioPortfolio]

Oxygen [Isis Medical, Inc.]

Pur-wash [Niagara Pharmaceuticals Inc.]


Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

PubMed Articles [145 Associated PubMed Articles listed on BioPortfolio]

Injury and death during the ISIS occupation of Mosul and its liberation: Results from a 40-cluster household survey.

Measurement of mortality and injury in conflict situations presents many challenges compared with stable situations. However, providing information is important to assess the impact of conflict on pop...

Truck attack: Fear of ISIS and reminder of truck attacks in Europe as associated with psychological distress and PTSD symptoms.

Following an ISIS attack, the present study examined the association between psychological distress and severe stress symptoms with vulnerability variables: i.e. Physical proximity to the site of the ...

Can scalar timing explain variability in scanning patterns?

Why are scanning patterns so variable? Theory predicts that for prey species facing non-stalking predators scans to monitor predators should occur at fixed rather than unpredictable times. Yet, empiri...

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Chiral pharmaceuticals: Environment sources, potential human health impacts, remediation technologies and future perspective.

Chiral pharmaceuticals (CPs), including non-steroid anti-inflammatory drugs (NSAIDs), β-blockers and some herbicide and pesticides, are widely used in aquaculture, clinical treatment and many other f...

Clinical Trials [280 Associated Clinical Trials listed on BioPortfolio]

A Double Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 353512 Administered Intravenously and Subcutaneously to Healthy Volunteers

The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of ISIS 353512, to evaluate the blood concentration and rate elimination of ISIS 353512 fr...

The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes

To evaluate the efficacy and safety of ISIS 2922 in AIDS patients with Cytomegalovirus ( CMV ) retinitis who are unresponsive or intolerant to ganciclovir and/or foscarnet but are otherwis...

Dose-Escalating Safety Study in Subjects on Stable Statin Therapy

The aim of this study is to assess the safety of varying doses of ISIS 301012 in subjects on Stable statin therapy.

Study of ISIS 301012 in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 as add-on therapy in subjects with Heterozygous Familial Hypercholesterolemia

A Study of Multiple Doses of ISIS SMNRx (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

The primary objective of the study is to examine the efficacy of multiple doses of ISIS SMNRx (ISIS 396443) administered intrathecally in preventing or delaying the need for respiratory in...

Companies [1347 Associated Companies listed on BioPortfolio]

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Isis Innovation

Isis Innovation is the technology transfer company of the University of Oxford, commercialising the research generated by University researchers and owned by the University.Isis Innovation Ltd is a wh...

Isis Parenting Inc.

Isis Parenting is the nation’s leading provider of prenatal and early parenting education. Isis partners with leading healthcare institutions to offer over their patients ove...

Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals

Isis Pharmaceuticals, Inc. is a leading drug discovery and development company, focused exclusively on the therapeutic target, RNA. Founded in 1989, Isis' mission is to develop products from its RNA-b...

More Information about "Isis Pharmaceuticals" on BioPortfolio

We have published hundreds of Isis Pharmaceuticals news stories on BioPortfolio along with dozens of Isis Pharmaceuticals Clinical Trials and PubMed Articles about Isis Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Isis Pharmaceuticals Companies in our database. You can also find out about relevant Isis Pharmaceuticals Drugs and Medications on this site too.

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Antisense therapy
Most human diseases are caused by production of abnormal proteins or malfunctioning proteins.   Antisense therapy involves inhibiting production of these proteins.  When a gene is known to cause a specific disease and the genetic sequence ...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Corporate Database Quicklinks

Searches Linking to this Company Record